IP Library › Granted Patent US 12,653,911
Granted Patent B2
US 12,653,911 · App. 17/585,118 · Granted Jun 16, 2026

Stimuli-responsive nanoparticles for biomedical applications

Inventors: Xiaoding Xu (Boston, MA); Jinjun Shi (Boston, MA); Omid C. Farokhzad (Boston, MA)
Assignee: The Brigham And Women's Hospital, Inc.
A61K49/0054A61K9/1273A61K9/5138A61K9/5146A61K9/5153A61K47/65A61K49/0021A61K49/0032C08F293/005A61K31/711A61K49/0093C08F220/286C08F220/34C08F2438/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,911
App. No.
17/585,118
Granted
Jun 16, 2026
Kind
B2
Abstract

Stimuli-responsive NPs with excellent stability, high loading efficiency, encapsulation of multiple agents, targeting to certain cells, tissues or organs of the body, can be used as delivery tools. These NPs contain a hydrophobic inner core and hydrophilic outer shell, which endows them with high stability and the ability to load therapeutic agents with high encapsulation efficiency. The NPs are preferably formed from amphiphilic stimulus-responsive polymers or a mixture of amphiphilic and hydrophobic polymers or compounds, at least one type of which is stimuli-responsive. These NPs can be made so that their cargo is released primarily within target certain cells, tissues or organs of the body, upon exposure to endogenous or exogenous stimuli. The rate of release can be controlled so that it may be a burst, sustained, delayed, or a combination thereof. The NPs have utility as research tools or for clinical applications including diagnostics, therapeutics, or combination of both.

Claims (15)

1 . A stimulus responsive polymer comprising:

(a) a hydrophilic portion; and

(b) a hydrophobic portion modified with a charged group,

wherein the hydrophilic portion and the hydrophobic portion are connected by a covalent linker; and

wherein the stimulus responsive polymer comprises Formula I: (X) m —(Y) n ,

wherein m and n are independently integers between one and 1000, X is a hydrophobic polymer in the hydrophobic portion and comprises a glycidyl methacrylate and Y is a hydrophilic polymer in the hydrophilic portion and comprises polyethylene glycol, and

wherein the polymer comprises methoxyl-polyethylene glycol-b-poly (2-(diisopropylamino) ethylmethacrylate-co-glycidyl methacrylate-tetraethylenepentamine-C14) (Meo-PEG-b-P (DPA-CO-GMA-TEPA-C14)).

2 . The stimulus responsive polymer of claim 1 , wherein the charged group comprises a positive charge.

3 . The stimulus responsive polymer of claim 1 , wherein the stimulus comprises a pH buffer.

4 . The stimulus responsive polymer of claim 3 , wherein the buffer comprises a pH of about 4 to about 7.5.

5 . The stimulus responsive polymer of claim 4 , wherein the buffer comprises a pH of about 5 to about 7.

6 . The stimulus responsive polymer of claim 1 , wherein the hydrophobic portion further binds a nucleic acid.

7 . The stimulus responsive polymer of claim 1 , wherein the stimulus responsive polymer has a pKa between 6.0 and 6.5.

8 . The stimulus responsive polymer of claim 1 , wherein the stimulus responsive polymer is complexed with a nucleic acid.

9 . The stimulus responsive polymer of claim 8 , wherein the nucleic acid is an antisense oligonucleotide, an siRNA, a shRNA, an miRNA, a piRNA, an external guide sequence (EGS), a ribozyme, or an aptamer.

Assignments (2)
LICENSE Recorded Dec 20, 2024
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 069748/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2022
From: XU, XIAODING; SHI, JINJUN; FAROKHZAD, OMID C.
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 059540/0876 →
Continuity (3)
Continuation 16090551
Provisional Application 62317033 · Apr 1, 2016
Related Publication 20220226510A1 · Jul 21, 2022
References Cited (27)
US 20100034748A1 · Li · 2010 [cited by examiner]
US 20130136714A1 · Wang · 2013 [cited by examiner]
CN 104231193 · 2014 [cited by applicant]
WO 2013152059 · 2013 [cited by applicant]
WO 2016040814 · 2016 [cited by applicant]
https://www.thermofisher.com/antibody/product/CD31-Antibody-clone-2H8-Monoclonal/MA3105#:˜:text=The%20MA3105%20immunogen%20is%20mouse%20PECAM1%20%28CD31%29.%20MA3105,a%20predicted%20molecular%20weight%20of%20approximate… [cited by examiner]
Almeida, et al., “Temperature and pH stimuli-responsive polymers and their applications in controlled and self-regulated drug delivery,” J. Applied Pharm. Sci., 02(06):1-10 (2012). [cited by applicant]
Chen, et al., “Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment,” Theranostics, 7(3):538-558 (2017). [cited by applicant]
Du, et al., “Synthesis and Characterization of Photo-Cross-Linked Hydrogels Based on Biodegradable Polyphosphoesters and Poly(ethylene glycol) Copolymers,” Biomacromolecules, 8(11):3375-3381 (2007). [cited by applicant]
Gandhi, et al., “Nanocarrier mediated Delivery of siRNA/miRNA in Combination with Chemotherapeutic Agents for Cancer Therapy: Current Progress and Advances”, J. Control. Release, 0:238-256 (2014). [cited by applicant]
Haijun, et al., “Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles,” Biomaterials, 34(11):2738-2747 (2013). [cited by applicant]
International Search Report for PCT/US2017/025772 mailed Jun. 28, 2017. [cited by applicant]
James, et al., “Smart polymers for the controlled delivery of drugs—a concise overview,”Acta Pharma. Sinica B, 4(2):120-127 (2014). [cited by applicant]
Knop, et al., “Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives,” Angew. Chem. International Edition, 49(36): 6288-6308 (2010). [cited by applicant]
Lewis, et al., “Using Polymers as Endosomal Escape Agents for siRNA Delivery in vivo”, TIDES Pre-Conference Workshop, 33 pages, May 12, 2014. [cited by applicant]
Li, et al., “Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes,” Journal of Controlled Release, 220(Pt B):704-714 (2015). [cited by applicant]
Mabrouk, et al., “Bursting of sensitive polymersomes including by curling,” Proceedings National Academy of Sciences PNAS, 106(18):7294-7298 (2009). [cited by applicant]
Ryther, et al., “siRNA therapeutics: big potential from small RNAs”, Gene Therapy, 12:5-11 (2005). [cited by applicant]
Sommer, et al., “Inflammation, tissue repair and fever, Essential of Pathophysiology—Concepts of Altered Health Sciences”, 9: 495-514 (2006). [cited by applicant]
Wang, et al., “A Broad Nanoparticle-Based Strategy For Tumor Imaging by Nonlinear Amplification of Microenvironment Signals,” Nature Materials, 13(2):204-212 (2013). [cited by applicant]
Wang, et al., “Hierarchical Targeting Strategy for Enhanced Tumor Tissue Accumulation/Retention and Cellular Internalization,” Advanced materials, 28(34):7340-7364 (2016a). [cited by applicant]
Wang, et al., “Stimuli-Responsive Programmed Specific Targeting in Nanomedicine,” ACS Nano 10(3):2991-2994 (2016b). [cited by applicant]
Xu, et al., “Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug,” Proc Natl Acad Sci USA, 110(46):18638-18643 (2013). [cited by applicant]
Xu, et al., “Multi-functional Envelope-Type siRNA Delivery Nanoparticle platform for Prostate Cancer Therapy,” ACS Nano, 11(3):2618-2627 (2017). [cited by applicant]
Xu, et al., “Ultra-pH Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy,” Angew Chem International Edition, 55(25):7091-7094 (2016). [cited by applicant]
Yin, et al., “Crosslinked triblock copolymeric micelle for redox-responsive drug delivery,” Colloids and Surfaces B Biointerfaces, 122:223-230 (2014). [cited by applicant]
Yu, et al. “Triple-Layered pH-Responsive Micelleplexes Loaded with si RNA and Cisplatin Prod rug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer”, Theranostics, 6(1): 14- 27 (2016). [cited by applicant]